Alcohol Use Disorder Treatment Pipeline Analysis 2019 (H1)

Report
109 Pages
May 2019
Region: Global
Knowledge Sourcing Intelligence LLP
ID: 4801768

Alcohol use disorder or alcohol dependence treatment pipeline analysis report covers more than 10 drugs currently in different phases of development. Alcohol dependence is a medical and behavioral disease which is characterized by alcohol-induced disturbances in brain structure, neurochemistry, and behavior. The major characteristics of alcohol dependence is an extreme urge to consume alcohol and difficulties in controlling the consumption of alcohol despite harmful consequences. Overcoming addiction is generally a long process that requires both personal will to give up alcohol along with various treatments or therapies.

The report provides alcohol use disorder treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are Addexx Therapeutics, Silence Therapeutics Plc, Curemark LLC among others.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration

1. Introduction

1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview

2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

6.1. Savant HWP, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Addexx Therapeutics
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Opiant Pharmaceuticals, Inc
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. Omeros Corp
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. Adial Pharmaceuticals
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Montisera Ltd
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. Ethypharm SA
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Medicinova
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. Amygdala Neurosciences, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Curemark LLC
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. Kinnov Therapeutics
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
6.12. BioCorRx, Inc
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.12.5. Recent Development
6.13. Corcept Therapeutics Inc
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.13.5. Recent Development
6.14. Bionex Pharmaceuticals LLC
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.14.5. Recent Development
6.15. Bioprojet SCR
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.15.5. Recent Development
6.16. Chronos Therapeutics Ltd
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.16.5. Recent Development
6.17. Lohocla Research Corp
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.17.5. Recent Developments
6.18. Lohocla Research Corp
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.18.5. Recent Developments
6.19. Silence Therapeutics Plc
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.19.5. Recent Developments
6.20. Syntropharma Limited
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.20.5. Recent Developments
6.21. Laboratorio Farmaceutico Ct S.r.l.
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.21.5. Recent Development
6.22. Pop Test Oncology LLC
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.22.5. Recent Development

Companies Mentioned

Savant HWP, Inc.
Addexx Therpeutics
Opiant Pharmaceuticals, Inc
Omeros Corp
Adial Pharmaceuticals
Montisera Ltd
Ethypharm SA
Medicinova
Amygdala Neurosciences, Inc.
Curemark LLC
Kinnov Therapeutics
BioCorRx, Inc
Corcept Therapeutics Inc
Bionex Pharmaceuticals LLC
Bioprojet SCR
Chronos Therapeutics Ltd
Lohocla Research Corp
Lohocla Research Corp
Silence Therapeutics Plc
Syntropharma Limited
Laboratorio Farmaceutico Ct S.r.l.
Pop Test Oncology LLC

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2799EUR$2,900USD£2,401GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5695EUR$5,900USD£4,885GBP

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Alcohol Addiction Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Alcohol Use Disorder - Pipeline Insight, 2024

Alcohol Addiction - Pipeline Insight, 2024

Alcohol Use Disorder (AUD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Alcohol Abuse Monitoring Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type